S. Comte

Naftidrofuryl in intermittent claudication: a retrospective analysis.

P. Lehert, T. Brown, S. Comte, 1994, Journal of cardiovascular pharmacology.

The long-term cost-effectiveness of improving alcohol abstinence with adjuvant acamprosate.

A. Palmer, M. Fox, K. Neeser, 2000, Alcohol and alcoholism.

Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials.

Murielle Mauer, Corneel Coens, Andrew Bottomley, 2009, The Lancet. Oncology.

The Claudication Scale (CLAU-S)

T. Brown, S. Dietze, I. Kirchberger, 1997 .

Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab.

K. Ang, P. Harari, J. Jassem, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Glycemic control and cardiovascular disease in Type 2 diabetes: a review

S. Wild, P. McKeigue, C. Dunn, 1999, Diabetes/metabolism research and reviews.

[Epidemiology and costs of lung cancer in France].

B. Detournay, S. Comte, M. Zélicourt, 2001, Bulletin du Cancer.

A critical review of pharmacoeconomic studies of acamprosate.

A. Palmer, D. Haeger, F. Poldrugo, 2005, Alcohol and alcoholism.

International Validation of the CLAU-S Quality-of-Life Questionnaire for Use in Patients with Intermittent Claudication

P. Marquis, P. Lehert, S. Comte, 2012, PharmacoEconomics.

A pragmatic trial of acamprosate in the treatment of alcohol dependence in primary care.

P. Lehert, D. Huas, F. Paille, 2004, Alcohol and alcoholism.